# Daily Iteration Report — 2026-06-21 (Sunday)

**Agent:** Diabetes Research Hub automated research agent
**State:** `Analysis/Results/agent_state.json` (loaded + saved)

## Summary
Routine maintenance run. No backlog. Two oldest stale research paths re-validated against current 2025/2026 evidence; both correctly held at PARTIALLY_VALIDATED. Pipeline fully green. Git push remains blocked in sandbox (user action required).

## State snapshot
| Item | Count |
|---|---|
| Papers | 285 (272 VETTED-clean / 13 FLAGGED legit off-topic) — **0 backlog** |
| Research paths | 57 (38 VALIDATED, 16 PARTIALLY_VALIDATED, 3 CONTRADICTED) |
| Gaps | 15 (4 GOLD, 8 SILVER, 1 EXPLORATORY, 2 BRONZE) |
| Work queue | 23 items; most date-gated to Jul–Sep 2026 |

## Work performed

### 1. Credibility sweep — CLEAN
- No fabricated PMIDs (>42,000,000) in any script.
- No "zero SAEs" / "zero rejection" language.
- Only "curative"/"achieves" hits are the detector regexes in `verify_before_deploy.py` and legitimate mechanism/cost-effectiveness descriptions. No overstated clinical claims.

### 2. Path re-validation ×2 (oldest stale paths)
**rapamycin → inflammation** (last validated 2026-03-20) — **REAFFIRMED PARTIALLY_VALIDATED**
- Effect remains preclinical and context-dependent: rapamycin reverses inflammatory-cytokine-induced IRS-1 serine phosphorylation and restores PI3K/AKT insulin signaling in vitro/in vivo ([PMC4598825](https://pmc.ncbi.nlm.nih.gov/articles/PMC4598825/)); single-dose attenuates post-ischemic cardiac fibrosis + inflammation in a diabetic model ([PMC10218967](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218967/)).
- Counter-evidence: mTOR inhibition is paradoxical — induces hyperglycemia / new-onset diabetes in 13–50% of oncology trials ([PMID 26421362](https://pubmed.ncbi.nlm.nih.gov/26421362/)). No human anti-inflammatory RCT in a diabetes population.
- Added external PMID: PMC4598825.

**GLP1_RA → T1D** (last validated 2026-04-21) — **REAFFIRMED PARTIALLY_VALIDATED**
- New evidence strengthens the *adjunctive metabolic* benefit: 25-RCT systematic review/meta-analysis ([PMC12678461](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678461/)), 2026 Nature Medicine CV/kidney-outcomes analysis, and ADA Standards of Care 2026 ([PMC12690185](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690185/)).
- Beta-cell-preservation half stays **unvalidated**: liraglutide showed no significant C-peptide preservation in T1D. SHIELD-T1D ([NCT07614412](https://clinicaltrials.gov/study/NCT07614412)) ongoing.
- No rating change — honest outcome consistent with research doctrine.

### 3. Pipeline rebuild — ALL 41 stages [OK]
`run_quality_improvements.py` completed cleanly, including both network stages this run (PubMed PMID verification + PMC abstract/full-text ingest).

## Blocker (unchanged, requires user)
Git commit/push is **blocked in the sandbox**: a stale 0-byte `.git/index.lock` (Jun-19) cannot be removed (`Operation not permitted` — OneDrive). `git status` reads fine, but any commit creates a new lock and fails. All changes are saved to working files for the next user push.

**User fix (PowerShell in the OneDrive copy):**
1. Close any git GUI/editor.
2. `del .git\index.lock`
3. Optional cleanup: `Get-ChildItem .git\index.* -Exclude index | Remove-Item -Force`
4. `git add -A; git commit -m 'sync 2026-06-21 daily iteration'; git push`

## Notes
- Sunday — weekly (Monday-only) PubMed new-paper sweep skipped.
- Queue items for verapamil/Ver-A-T1D, Abata ABA-201, tegoprubart, SAB-142, etc. are date-gated (next checks Jul–Sep 2026); not yet due.

*Research synthesis only — not medical advice.*
